NYSEMKT: NRXSNeuraxis Inc Stock
$2.29-0.01 (-0.43%)
Updated Jun 13, 2025
NRXS Price
$2.29
Fair Value Price
N/A
Market Cap
$16.52M
52 Week Low
$1.33
52 Week High
$6.20
P/E
-1.89x
P/B
63.93x
P/S
5.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.93M
Earnings
-$8.40M
Gross Margin
85.9%
Operating Margin
-281.08%
Profit Margin
-300.7%
Debt to Equity
10.72
Operating Cash Flow
-$6M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NRXS's potential to beat the market
- NRXS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NRXS
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important NRXS news, forecast changes, insider trades & much more!
NRXS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NRXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRXS is poor value based on its book value relative to its share price (63.93x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
NRXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRXS due diligence checks available for Premium users.
Valuation
NRXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.89x
Industry
-108.97x
Market
31.36x
NRXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
63.93x
Industry
4.66x
NRXS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRXS's financial health
Profit margin
Revenue
$895.7k
Net Income
-$2.3M
Profit Margin
-278.3%
NRXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NRXS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.0M
Liabilities
$2.8M
Debt to equity
10.72
NRXS's short-term assets ($2.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRXS's short-term assets ($2.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$18.0k
Financing
-$69.8k
NRXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRXS vs Biotech Stocks
Neuraxis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.